Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jul;39(7):1580–1588. doi: 10.1128/aac.39.7.1580

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.

B P Goldstein 1, G Candiani 1, T M Arain 1, G Romanò 1, I Ciciliato 1, M Berti 1, M Abbondi 1, R Scotti 1, M Mainini 1, F Ripamonti 1, et al.
PMCID: PMC162785  PMID: 7492108

Abstract

MDL 63,246 is a semisynthetic derivative of the naturally occurring glycopeptide antibiotic MDL 62,476 (A40926). It was more active in vitro against Staphylococcus aureus and coagulase-negative staphylococci than MDL 62,476, teicoplanin, and vancomycin and was more active than mideplanin (MDL 62,873) against some isolates. MDL 63,246 had excellent activity against streptococci and teicoplanin-susceptible enterococci, and it also had in vitro activity against some VanA enterococcal isolates. It was more active than teicoplanin and vancomycin against acute staphylococcal, streptococcal, and enterococcal septicemia in immunocompetent and neutropenic mice. It was highly efficacious in reducing the bacterial load in the hearts of rats in staphylococcal endocarditis experiments and the bacterial load of Staphylococcus epidermis in a high infection model in neutropenic mice. The excellent in vivo activity of MDL 63,246 appears to correlate both with its in vitro antibacterial activity and with its long half-life in rodents.

Full Text

The Full Text of this article is available as a PDF (255.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aubert G., Passot S., Lucht F., Dorche G. Selection of vancomycin- and teicoplanin-resistant Staphylococcus haemolyticus during teicoplanin treatment of S. epidermidis infection. J Antimicrob Chemother. 1990 Mar;25(3):491–493. doi: 10.1093/jac/25.3.491. [DOI] [PubMed] [Google Scholar]
  2. Bartoloni A., Colao M. G., Orsi A., Dei R., Giganti E., Parenti F. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother. 1990 Nov;26(5):627–633. doi: 10.1093/jac/26.5.627. [DOI] [PubMed] [Google Scholar]
  3. Berti M., Candiani G., Borgonovi M., Landini P., Ripamonti F., Scotti R., Cavenaghi L., Denaro M., Goldstein B. P. Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections. Antimicrob Agents Chemother. 1992 Feb;36(2):446–452. doi: 10.1128/aac.36.2.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Biavasco F., Lupidi R., Varaldo P. E. In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873. Antimicrob Agents Chemother. 1992 Feb;36(2):331–338. doi: 10.1128/aac.36.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brumfitt W., Maple P. A., Hamilton-Miller J. M. Ramoplanin versus methicillin-resistant Staphylococcus aureus: in vitro experience. Drugs Exp Clin Res. 1990;16(8):377–383. [PubMed] [Google Scholar]
  6. Campoli-Richards D. M., Brogden R. N., Faulds D. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1990 Sep;40(3):449–486. doi: 10.2165/00003495-199040030-00007. [DOI] [PubMed] [Google Scholar]
  7. Clark N. C., Cooksey R. C., Hill B. C., Swenson J. M., Tenover F. C. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother. 1993 Nov;37(11):2311–2317. doi: 10.1128/aac.37.11.2311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goldstein B. P., Selva E., Gastaldo L., Berti M., Pallanza R., Ripamonti F., Ferrari P., Denaro M., Arioli V., Cassani G. A40926, a new glycopeptide antibiotic with anti-Neisseria activity. Antimicrob Agents Chemother. 1987 Dec;31(12):1961–1966. doi: 10.1128/aac.31.12.1961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldstein F. W., Coutrot A., Sieffer A., Acar J. F. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother. 1990 May;34(5):899–900. doi: 10.1128/aac.34.5.899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gordon S., Swenson J. M., Hill B. C., Pigott N. E., Facklam R. R., Cooksey R. C., Thornsberry C., Jarvis W. R., Tenover F. C. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group. J Clin Microbiol. 1992 Sep;30(9):2373–2378. doi: 10.1128/jcm.30.9.2373-2378.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jones R. N., Goldstein F. W., Zhou X. Y. Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States. Antimicrob Agents Chemother. 1991 Mar;35(3):584–586. doi: 10.1128/aac.35.3.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kenny M. T., Brackman M. A., Dulworth J. K. In vitro activity of the semisynthetic glycopeptide amide MDL 63,246. Antimicrob Agents Chemother. 1995 Jul;39(7):1589–1590. doi: 10.1128/aac.39.7.1589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Leclercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988 Jul 21;319(3):157–161. doi: 10.1056/NEJM198807213190307. [DOI] [PubMed] [Google Scholar]
  14. Murray B. E. The life and times of the Enterococcus. Clin Microbiol Rev. 1990 Jan;3(1):46–65. doi: 10.1128/cmr.3.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Schwalbe R. S., Stapleton J. T., Gilligan P. H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 1987 Apr 9;316(15):927–931. doi: 10.1056/NEJM198704093161507. [DOI] [PubMed] [Google Scholar]
  16. Scotti R., Dulworth J. K., Kenny M. T., Goldstein B. P. Effect of protein on ramoplanin broth microdilution minimum inhibitory concentrations. Diagn Microbiol Infect Dis. 1993 Oct;17(3):209–211. doi: 10.1016/0732-8893(93)90098-r. [DOI] [PubMed] [Google Scholar]
  17. Selva E., Goldstein B. P., Ferrari P., Pallanza R., Riva E., Berti M., Borghi A., Beretta G., Scotti R., Romanò G. A40926 aglycone and pseudoaglycones: preparation and biological activity. J Antibiot (Tokyo) 1988 Sep;41(9):1243–1252. doi: 10.7164/antibiotics.41.1243. [DOI] [PubMed] [Google Scholar]
  18. Uttley A. H., George R. C., Naidoo J., Woodford N., Johnson A. P., Collins C. H., Morrison D., Gilfillan A. J., Fitch L. E., Heptonstall J. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect. 1989 Aug;103(1):173–181. doi: 10.1017/s0950268800030478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Veach L. A., Pfaller M. A., Barrett M., Koontz F. P., Wenzel R. P. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol. 1990 Sep;28(9):2064–2068. doi: 10.1128/jcm.28.9.2064-2068.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Woodford N., Johnson A. P., Morrison D., Chin A. T., Stephenson J. R., George R. C. Two distinct forms of vancomycin resistance amongst enterococci in the UK. Lancet. 1990 Jan 27;335(8683):226–226. doi: 10.1016/0140-6736(90)90317-x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES